ArticleInvestigative ophthalmology & visual science2025
Potential Application of Bendazac L-Lysine for Controlling Myopia Progression, as Demonstrated in Two Experimental Guinea Pig Myopia Models.
Article in Investigative ophthalmology & visual science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Myopia is a common refractive error that is emerging as a major concern worldwide, because it is not clear how best to treat it. To improve therapeutic management of this condition, novel favorable risk-benefit profiles and accessible approaches are urgently needed. Here, we evaluate the efficacy of bendazac L-lysine (BDL) for attenuating experimental myopia in guinea pigs. Methods: Three-week-old pigmented guinea pigs wore occluders or -4.00 diopter (D) lenses on the right eye to induce either form-deprivation myopia (FDM) or lens-induced myopia (LIM), respectively. Simultaneously, (1) induced-myopic eyes received daily peribulbar injections of the aldose reductase inhibitors (ARIs) sorbinil, zopolrestat, or BDL during FDM or LIM. (2) FDM eyes received daily peribulbar injections of one of four doses of BDL, or twice-daily BDL eye drops or ointment. (3) FDM eyes received daily peribulbar injections of either bendazac or L-lysine. (4) Guinea pigs that were not subjected to myopia induction (normal vision) received daily peribulbar injections of BDL. The effects on refraction, axial length, and choroidal thickness (ChT) were measured after treatment. Results: Sorbinil and zopolrestat had no effect on FDM, whereas BDL inhibited FDM and LIM development. BDL treatment, regardless of peribulbar injection, eye drops, or ointment, suppressed FDM. Bendazac, rather than L-lysine, is the active ingredient in BDL. The BDL significantly inhibited either FDM or LIM associated decrease in ChT, without altering ChT during normal ocular growth. Conclusions: BDL significantly suppressed myopia development in experimentally induced myopia in guinea pigs. This study suggests that BDL may be a viable candidate for myopia control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.